Medichronal-Darnitsa granules set 2p x 1 piece (4 bags) — Made in Ukraine — Free Delivery

Medichronal-Darnitsa is a combined agent that helps to reduce the accumulation of toxic alcohol metabolites in the body, in particular acetaldehyde (a product of ethanol oxidation).

The preparation has a detoxification effect, improves metabolic processes in the body, enhances the synthesis of catecholamines, especially norepinephrine, which improves neuromediation processes, stimulates the limbic-reticular complex, and increases the functional activity of the cerebral cortex.

The preparation Medichronal-Darnitsa has a positive effect on liver function, and also improves sleep, general well-being.

Reduction of symptoms of acute alcohol intoxication, symptoms of mild and moderate withdrawal symptoms occurs within 20-30 minutes after taking the preparation.

Aminoacetic acid is rapidly absorbed in the gastrointestinal tract. Has almost 100% bioavailability. Easily penetrates into most body fluids and tissues. It is destroyed in the liver by the enzyme glycine oxidase.

Sodium formate is rapidly absorbed in the gastrointestinal tract. In the systemic circulation and body tissues, it reacts with acetaldehyde to form conjugates, which take part in the tricarboxylic acid cycle, and increases the formation of high-energy compounds.

Alcohol intoxication, withdrawal symptoms; to improve the effectiveness of other therapies; intoxication prevention; secondary prevention of alcoholism.

Medichronal-Darnitsa is used in adults after meals, after dissolving the contents of both packets in ½ – ¾ glass (200 ml) of warm water. a single dose is 28.5 g (the total weight of the components of both packages). to improve the taste, the contents of the bags can be dissolved in non-carbonated drinks (juice, compote, etc.).

To eliminate acute alcoholic and withdrawal conditions, the preparation is used on the first day 1-2 times (after 10-12 hours) at a dose of 28.5 g, in the next 2-3 days - 28.5 g once a day.

In combination with other preparations in the treatment of chronic alcoholism and, if necessary, secondary prevention, this preparation is taken daily in one package (28.5 g) for 7 days in the form of 3 courses with a 3-day break between them. To prevent relapses 1–1.5 months after the course of treatment with Medichronal-Darnitsa, it is recommended to undergo a repeated 30-day course of therapy. It is also possible to use from 1 to 3 repeated short-term preventive courses of treatment (7-14 days) throughout the year.

For the prevention of intoxication, it is necessary to take a single dose (contents of packages No. 1 and No. 2) 30 minutes before drinking alcoholic beverages.

Hypersensitivity to the components of the preparation; severe forms of diabetes mellitus, arterial hypotension.

All components of Medichronal-Darnitsa are natural metabolites, therefore it is well tolerated. in some cases, such side reactions are possible:

from the nervous system: headache, tension, irritability, deterioration in concentration;

from the gastrointestinal tract: nausea;

from the immune system: hypersensitivity reactions, including rash, itching, urticaria.

Medichronal-Darnitsa can be used both independently and in complex treatment. when prescribing treatment, it is necessary to use an individual approach, which may include a change in the duration of treatment or an increase in the number of repeated courses throughout the year.

In patients with a tendency to arterial hypotension, it is necessary to control the level of blood pressure and, if necessary, adjust the dose of the preparation (prescribed in lower doses, subject to regular monitoring of blood pressure). With a decrease in blood pressure below the usual level, the preparation is canceled.

Since the preparation contains glucose, its use is limited by conditions accompanied by hyperglycemia.

Use during pregnancy and lactation. Strictly controlled and adequate studies on the efficacy and safety of the preparation  in pregnant women and women who are breastfeeding have not been conducted, therefore, use during pregnancy is possible if the benefit to the mother outweighs the potential risk to the fetus.

The ability to influence the reaction rate when driving or working with other mechanisms. During treatment, care should be taken when driving vehicles and working with complex mechanisms.

Children. Studies on the efficacy and safety of the preparation in children have not been conducted.

The active ingredient of the preparation - glycine - reduces the toxicity of anticonvulsants, antipsychotics, antidepressants, anticonvulsants.

With the combined use of the preparation with tranquilizers, hypnotics and antipsychotics, the effect of inhibition of the central nervous system is enhanced.